Latest news with #Theratechnologies
Yahoo
29-05-2025
- Business
- Yahoo
Theratechnologies Reports on its Annual Meeting of Shareholders
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company's Board of Directors for a one-year term, appointed KPMG LLP as the Company's auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries. All candidates proposed for the position of director were elected in the following proportion: FOR % FOR ABSTENTION % ABSTENTION Joseph Arena 20,473,944 84.03% 3,890,222 15.97% Frank Holler 19,089,786 78.35% 5,274,380 21.65% Paul Lévesque 19,027,772 78.10% 5,336,394 21.90% Andrew Molson 19,066,145 78.25% 5,298,021 21.75% Dawn Svoronos 18,998,230 77.98% 5,365,936 22.02% Elina Tea 19,163,502 78.65% 5,200,664 21.35% Dale Weil 19,005,768 78.01% 5,358,398 21.99% Jordan Zwick 19,618,725 80.52% 4,745,441 19.48% About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at on SEDAR+ at and on EDGAR at Follow Theratechnologies on Linkedin and X (formerly Twitter). Contacts: Investor inquiries:Philippe DubucSenior Vice President and Chief Financial Officerpdubuc@ Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@ in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
Theratechnologies Provides Update on Sale Process
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the 'Board') has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the 'Special Committee'), to oversee the process and make a recommendation to the full Board. To support this process, in addition to Barclays as financial advisor and Fasken as legal advisor, the Special Committee has also engaged Raymond James as independent financial advisor and Norton Rose Fulbright as independent legal advisor. There is no assurance that discussions with Future Pak or any other interested party will result in a transaction. The Company would like to reassure its clients, employees and partners that while these discussions may be ongoing, operations continue in the normal course. The Company does not intend to provide further updates or comments with respect to the foregoing, other than as required pursuant to applicable securities laws. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at on SEDAR+ at and on EDGAR at Follow Theratechnologies on LinkedIn and X. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, 'Forward-Looking Statements'), within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as 'may', 'will', 'should', 'could', 'promising', 'would', 'outlook', 'believe', 'plan', 'envisage', 'anticipate', 'expect' and 'estimate', or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to: the unsolicited proposal received by the Company from Future Pak for the acquisition of the Company; the review and evaluation by the Special Committee of proposals received by the Company from potential acquirors; the process relating to such review and any potential outcomes thereof; and other statements that are not historical facts. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on this information since actual results may vary from the Forward-Looking Statements. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: the possibility that the Company, its Board, its Special Committee and a potential acquiror cannot come to an agreement on the terms and conditions of such potential acquiror's proposal or will not proceed with giving shareholders an opportunity to accept or vote in favour of such proposal; if a definitive agreement is reached, the failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, court and regulatory approvals and other conditions of closing necessary to complete the transaction; the possibility that the Special Committee's review does not result in a transaction; credit, market, currency, operational, commodity, geopolitical, liquidity and funding risks generally, including changes in economic conditions, interest rates or tax rates; the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of a transaction; other risks inherent to the Company's business and/or factors beyond its control which could have a material adverse effect on the Company or its ability to consummate a transaction to effect a potential acquiror's proposal. The Company refers current and potential investors to the 'Risk Factors' section of the Company's Annual Information Form filed on Form 20-F dated February 26, 2025 available on SEDAR+ at and on EDGAR at under Theratechnologies' public filings for the risks associated with the business. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. Contacts: Investor inquiries:Philippe Dubuc Senior Vice President and Chief Financial Officer pdubuc@ 438-315-6608 Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@ 514-336-7800
Yahoo
12-04-2025
- Business
- Yahoo
Future Pak submits proposals to acquire Theratechnologies
Future Pak announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies (THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51-$4.50 per share. The proposal represents a total enterprise value of up to $255M, comprising: $205 million in cash at closing, and Up to $50 million in contingent value right payments, including: 50% of the annual EGRIFTA(R) franchise gross profit above $30 million annually for three years post-closing. A $10 million one-time milestone payment if cumulative EGRIFTA gross profit exceeds $125 million over the same three-year period. This offer implies a 164% to 238% premium to Theratechnologies' closing stock price of $1.33 as of April 10, 2025. 'To move this process forward efficiently and deliver compelling value to Theratechnologies' shareholders, we have submitted multiple offers outlining a flexible and attractive framework,' said Nirav Patel, Chief Growth Officer at Future Pak. 'We believe this proposal provides significant upside and a solid foundation for constructive dialogue, with the goal of achieving a mutually beneficial transaction.' Despite repeated outreach and the submission of two detailed proposals-each offering a premium of more than 100% over Theratechnologies' trading price-Future Pak has received minimal engagement from the company to date. Future Pak confirms that the transaction would not be subject to a financing contingency and has the full support of its strategic financial partner, Colbeck Capital Management. Future Pak has engaged Bourne Partners Securities LLC as financial advisor and Honigman LLP as legal advisor. Given access to standard due diligence materials, Future Pak believes it could reach a definitive agreement and announce a transaction within four to six weeks. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on THTX: Disclaimer & DisclosureReport an Issue Theratechnologies Reports Strong Q1 2025 Growth Theratechnologies' Earnings Call: Growth Amid Challenges Theratechnologies Achieves Revenue Growth and Secures Key FDA Approvals in Q1 2025 Theratechnologies reports Q1 revenue $19.047M vs $16.247M last year Theratechnologies sees FY25 revenue $80M-$83M
Yahoo
11-04-2025
- Business
- Yahoo
Theratechnologies Shares Jump 42% After Future Pak's $255 Million Takeover Bid
Theratechnologies (THTX, Financials) shares surged 41.6% to 2.62 Canadian dollars ($1.91) as of 11:36 a.m. EDT on Friday after Future Pak disclosed two acquisition proposals valuing the company at up to $255 million. The Michigan-based contract manufacturer is offering between $3.51 and $4.50 per share in cash, representing a premium of 164% to 238% over Theratechnologies' April 10 closing price of $1.33. Warning! GuruFocus has detected 4 Warning Signs with THTX. The offer includes $205 million in cash at closing and up to $50 million in contingent value right payments tied to the performance of the EGRIFTA franchise. These contingent payments would cover 50% of annual gross profits above $30 million for three years, along with a one-time $10 million milestone if cumulative gross profit surpasses $125 million during the same period. Despite multiple outreach efforts, Future Pak said it has received limited engagement from Theratechnologies. By going public, the company said it hopes to encourage shareholder participation and push the board to consider the offer. The proposal is not subject to financing conditions and has backing from strategic partner Colbeck Capital Management. Future Pak is working with Bourne Partners Securities LLC as its financial adviser and Honigman LLP as legal counsel. The company said that with access to routine due diligence materials, a deal could be finalized within four to six weeks. Founded in 1977, Future Pak is a privately held manufacturer and packager of pharmaceutical and nutraceutical products, operating across retail, specialty, and institutional markets. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
26-03-2025
- Business
- Yahoo
TSX Sustains Triple-Digit Losses
Equities in Toronto took a breather from the dizzy heights of the past few days, as jitters over the impending tariffs promised by the White House filtered in investor behaviour. The TSX Composite Index reversed 178.45 points to close Wednesday at 25,161.06 The Canadian dollar ditched 0.04 cents to 70.02 cents U.S. In corporate news, Theratechnologies received FDA approval in the U.S. for a new treatment targeting abdominal fat in HIV patients. Theratechnologies shares galloped 47 cents, or 21.3%, to $2.68. Elsewhere in health-care, Tilray lost four cents, or 4.1%, to 96 cents, while Bausch Health Companies dropped 28 cents, or 2.8%, to $9.72. Electronic manufacturing services provider Celestica was the biggest loser on TSX, down $14.02, or 10.1%, to $125.04. Bitfarms shares were bruised 12 cents, or 7.8%, to $1.41. In materials, First Quantum Minerals dropped $1.29, or 5.7%, to $21.36, after Panama did not authorize visits to the miner's shuttered Cobre Panama mine. Teck Resources lost $3.72, or 6.1%, to $57.33. Telecoms tried to even things out, with TELUS shares forging ahead 30 cents, or 1.5%, to $20.19, while Rogers gained 37 cents, or 1%, to $39.53. Energy also rumbled on, with Arc Resources rocketing 62 cents, or 2.3%, to $28.87, while Paramount Resources tacked on 38 cents, or 2.1%, to $18.54. Industrials proved another gainer, as Boyd Group moved higher by $5.08, or 2.5%, or 2.5%, to $210.68, while Canadian National Railways moved forward $2.50, or 1.8%, to $142.84. ON BAYSTREET The TSX Venture Exchange dipped 8.57 points, or 1.3%, to 638.06. All but three of the 12 TSX subgroups were lower on the day, with information technology slumping 3.3%, health-care falling 2.6%, and materials suffering 1.6%. The three gainers were telecoms, up 0.9%, energy, upward 0.6%, and industrials, ahead 0.4%. ON WALLSTREET Read: AI Security Breaches and Quantum Hacks: Why Investors Are Watching This Space Quantum Computing's Security Risk: The $14.9 Billion Market Opportunity This Emerging Tech Could Disrupt the Entire Computing Industry—Is Your Portfolio Ready? From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 StrikePoint Gold gains momentum in Nevada's renowned Walker Lane Stocks dipped on Wednesday, led lower by tech, as pressure on the tariff front mounted. The Dow Jones Industrials lost 134.07 points to 42,453,43. The S&P 500 Index faltered 64.45 points, or 1.1%, to 5,712.20 The NASDAQ collapsed 372.84 points, or 2%, to 17,899.01 Other major tech names such as Meta, Amazon and Alphabet lost more than 2% each, while Tesla slid more than 5.5%. Stocks hit session lows after the White House said that President Donald Trump will unveil new tariffs on auto imports during a press conference at 4 p.m. ET. General Motors and Ford shares each dropped more than 1%, while Stellantis was down more than 2%. This will come ahead of a broad array of additional levies expected to be revealed next week. Trump on Tuesday said that these tariffs will likely be more 'lenient than reciprocal,' reflecting a softened stance that added onto reports from earlier this week that the duties could be more Prices for the 10-year Treasury faded Wednesday, hiking yields to 4.35% from Tuesday's 4.32%. Treasury prices and yields move in opposite directions. Oil prices gained 74 cents to $69.74 U.S. a barrel. Prices for gold handed back $3.70 to $3,022.20 U.S. Sign in to access your portfolio
